Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ Buys Pediatric Asthma Programs from Verus | Contract Pharma

What are you searching for?

Sign in
Breaking News

AZ Buys Pediatric Asthma Programs from Verus

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Verus Pharmaceuticals, Inc. sold its pediatric asthma development programs to AstraZeneca. This includes the North American rights to a Captisol enabled budesonide solution (controller medication), a short-acting beta agonist solution (rescue medication), a customized version of eFlow (novel nebulizer delivery device) for use with both medications, and other intellectual property and related assets from Verus.

Under the terms of the agreement, Verus will receive an upfront payment of $30 million, development expense reimbursements, and a potential earn-out payment of $280 million.

“We are excited to have completed this transaction with AstraZeneca, the North American leader in pediatric asthma treatment innovation, and are eager to collaborate with them to address the multiple unmet medical needs in this rapidly expanding patient population,” said Robert W. Keith, president and chief operating officer of Verus. “This transaction allows us to refocus our time and resources on our other emerging development programs, including those targeting unmet needs associated with related atopic diseases and conditions.”

“AstraZeneca is proud to be a part of these next generation development programs that hold the potential to help millions of children suffering from asthma and may positively impact their quality of life,” said Jim Helm, vice president respiratory primary care at AstraZeneca.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters